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Investigations of patients with suspected Mycoplasma pneumoniae infection have been
undertaken in England since the early 1970s. M. pneumoniae is a respiratory pathogen
that is a common cause of pneumonia and may cause serious sequelae such as
encephalitis and has been documented in children with persistent cough. The pathogen
is found in all age groups, with higher prevalence in children aged 5–14 years. In England,
recurrent epidemic periods have occurred at ∼4-yearly intervals. In addition, low-level
sporadic infection occurs with seasonal peaks from December to February. Voluntarily
reports from regional laboratories and hospitals in England from 1975 to 2015 were
collated by Public Health England for epidemiological analysis. Further data pertaining
cases of note and specimens submitted to Public Health England from 2005 to 2015 for
confirmation, molecular typing is included.
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INTRODUCTION
Mycoplasma pneumoniae is a respiratory bacterial pathogen causing upper and lower respiratory
disease in humans of all ages. It is a major cause of community-acquired pneumonia (CAP) and is
considered to be responsible for 15–20% of CAP cases in adults and up to 40% of cases in children,
especially in children of school age (Foy, 1993; Korppi et al., 2004; Dumke et al., 2012). Up to 25%
of M. pneumoniae infections may manifest as extra-pulmonary sequelae after the onset of or in
some cases in the absence of respiratory illness (Cassell and Cole, 1981; Narita, 2010). Encephalitis
is one of the most severe complications (Narita, 2009; Meyer Sauteur et al., 2014b) estimated in
5–10% of pediatric encephalitis patients (Bitnun et al., 2001; Christie et al., 2007) of which up to
60% of have additional neurologic sequelae (Bitnun et al., 2001, 2003). M. pneumoniae infection
can result in dermatological manifestations including Stevens-Johnson syndrome (Olson et al.,
2015). Hemolytic anemia is a rare but serious complication ofM. pneumoniae infection and is more
frequent children than in adults (Gu et al., 2014).M. pneumoniae infections occur both endemically
and epidemically worldwide, with epidemic peaks every 4–7 years (Chalker et al., 2011a, 2012a;
Jacobs, 2012). Typical outbreaks ofM. pneumoniae infection occur in areas of close personal contact
for example, schools and military barracks. Both symptomatic and asymptomatic individuals with
M. pneumoniae carry the organism in the respiratory tract and it can be transmitted from person
to person via aerosols and cough (Clyde, 1979; Waites and Talkington, 2004; Meyer Sauteur et al.,
2014c). Long-term morbidity due to M. pneumoniae infection is uncommon however; the acute
illness is often disruptive and can consume significant resources (Waites and Talkington, 2004).
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In England and Wales (EW), seasonal peaks of infection are
detected from December to February each year with epidemics
at ∼4-yearly intervals (Chalker et al., 2011b, 2015). Cyclical
patterns, as observed in EW, are also seen in Denmark, Sweden,
Norway, Finland, Korea, and Japan (Ito et al., 2001; Rasmussen
et al., 2010; Blystad et al., 2012; Linde et al., 2012; Polkowska
et al., 2012; Kim et al., 2015). It has recently been suggested that
minor variations in the duration of immunity may be essential
to the cyclic epidemic peaks (Omori et al., 2015). A con-current
increase in reported M. pneumoniae cases was documented in
several European countries in 2011 (Lenglet et al., 2012) and
in EW the most recent increase has been noted in 2015 (this
study).
The recent global increase in macrolide resistance observed in
cases of M. pneumoniae infection is of increasing concern and
importance to the international community (Bébéar, 2012). In
China resistance has been documents in over 90% of clinical
isolates of M. pneumoniae studied (Zhao et al., 2013) however
resistance is lower in European counties including France,
Germany, Switzerland, and Sweden (Peuchant et al., 2009;
Meyer Sauteur et al., 2014a; Nilsson et al., 2014; Dumke et al.,
2015). Macrolides are currently recommended as the first-line
treatment for M. pneumoniae infection in the UK (Harris et al.,
2011). The 2011 British Thoracic Society guidelines for the
management of CAP in children and adults suggest empirical
macrolide treatment at any age if there is no response to first-
line β-lactam antibiotics (which are ineffective against cell wall-
less bacteria such as M. pneumoniae) or in the case of very
severe disease (Lim et al., 2009; Harris et al., 2011). Macrolide-
resistance in EW has recently been documented at 9.3% and is
therefore not included in this article (Brown et al., 2015a). This
is considerably lower than in Scotland (19%) (Ferguson et al.,
2013).
This study aims to provide up to date overview of the number
of laboratory reports and incidence of M. pneumoniae infection
in EW, molecular typing data, and briefly highlight cases of note
in recent years.
MATERIALS AND METHODS
A total of 16,878 serological, culture, genomic, and unspecified
laboratory diagnostic methodologyM. pneumoniae positive cases
reported to Public Health England, via the Communicable
Disease Report Network comprising ∼250 laboratories from
January 1989 to June 2015 were aggregated into 3 weekly
periods. These report the organisms identified from specimens
(e.g., throat swabs, serum, or sputum) submitted by general
practitioners and hospitals with the patient’s age and sex, the
reporting laboratory, and date of the first sample; the system
has changed little over time. Duplicate specimens were removed
and reports plotted to examine the general pattern (3-weekly
moving average). National reporting categories include antibody
detection and antibody-detection rising titre. A rising titre is
defined as a four-fold increase in detectable anti-M. pneumoniae
antibody level. Rising titres are not demonstrated for all patients
as it is not always possible to obtain a second specimen. It is
possible that a fraction of cases reported as antibody detection
only include some cases of rising titre that have not been
appropriately coded. A distinction between IgA, IgG and IgM
cannot be made when collating figures, however the number
of cases with rising titre demonstrating active infection mirror
the overall total case pattern of epidemic periodicity. A total
of 39,758 laboratory reports of M. pneumoniae infections in
England and Wales from January 1975 to June 2009 previously
examined indicated that cyclic epidemics occurred every 4
years, were synchronous across all regions in the country, and
occurred during the winter (Nguipdop-Djomo et al., 2013).
Epidemic periods were defined as a clear increase in cases
resulting in more than 20 cases in a 3 weekly average rolling
period (Figure 1). From this dataset, we computed average
age specific incidence for epidemic and non-epidemic periods
using the England and Wales (EW) population censuses of
1981, and 2001 for the denominator for the periods 1975–
1988 and 1998–2009 respectively. Data from 1989 to 1997 were
excluded from age-specific analyses because age was missing in
∼90% records during that period. Age distribution incidence
rates from 2010 to June 2015 were calculated using the Office
for National Statistics (ONS) mid-year population estimates
for EW.
Diagnostic methodology of choice has altered with time in
EW, with the decline in culture and use of the complement
fixation test being superseded by enzyme immunosorbent assays
and the introduction of molecular testing. To ascertain the
proportion of reports now obtained using molecular methods,
differing methodologies in use with time was examined from
1989 to 2015 (Figure 2). Molecular typing of M. pneumoniae
positive clinical specimens and isolates was undertaken using
MLST (50) (Brown et al., 2015b), MLVA (156) (Chalker
et al., 2015), and P1 type (84) determinations (Dumke et al.,
2006) from 1977 to 2011 (Figures 3–5). Referred cases to the
Bacteriology Reference Department, Public Health England from
2005 to 2015 were examined for cases with unusual or severe
presentation.
RESULTS
From January 1989 to June 2015 seven epidemics of
M. pneumoniae were noted of declining amplitude with
recent peak in 2015 (Figure 1). For some epidemic periods clear
annual fluctuations can also be seen apparent as a double peak
over two winter seasons. The clarity of epidemic periods have in
recent years declined with less reported cases overall. From 1975
to 2009 incidence was found to be similar by gender, both during
epidemic and inter-epidemic periods. The annual notification
rate in 2010–2015 was consistently highest in those aged 15–44
years, detailed in Table 1. The use of culture has declined in
recent years and despite serology being the most commonly used
methodology the implementation and increased use of molecular
methods has resulted in a proportional increase in reports based
on molecular tests from 0.32% (3/936 95%CI 0.06–0.98) in 2010
to 28.5% (95/333 95%CI 24.0–33.6) in the first 6 months of 2015
(Figure 2). Molecular typing data were grouped into 4-yearly
Frontiers in Microbiology | www.frontiersin.org 2 February 2016 | Volume 7 | Article 157
Brown et al. Mycoplasma pneumoniae Epidemiology in England and Wales
FIGURE 1 | Laboratory reports of Mycoplasma pneumoniae infection detection by genomic and serological methods in England and Wales from
January 1989 to June 2015. The line at 20 cases per 3 weekly average rolling period defines seven epidemic periods of declining magnitude and clarity, lasting up to
2 years (1991–1992, 1994–1995, 1998–1999, 2001–2003, 2005–2006, 2011, 2015). National reporting categories include antibody detection and antibody-detection
rising titre. A rising titre is defined as a four-fold increase in detectable anti-Mycoplasma pneumoniae antibody level.
FIGURE 2 | Number of laboratory reports per year from January 1995 to June 2015 separated by detection methodology. National reporting categories
included are: antibody detection and antibody-detection rising titre. A rising titre is defined as a four-fold increase in detectable anti-Mycoplasma pneumoniae antibody
level (methods not specified). Other indicates specimens for which M. pneumoniae infection was determined using antigen detection (method not specified),
microscopy and unknown categories. Culture indicates cases from which specimens yielded isolates of M. pneumoniae and genomic detection those for which DNA
of M. pneumoniae was detected by PCR.
intervals, representing the epidemic cycles observed in the UK.
Multiple MLST, MLVA, and P1 types were observed in each
4-yearly interval (3–5) however a predominance of P1 type 1 can
be seen for all intervals except 1981–1984 where equal numbers
of P1 type 1 and type 2 strains were observed. This data is
limited by low sample number in 4-yearly intervals, therefore the
variation in P1 types observed is likely to be an underestimate of
the actualM. pneumoniae population present.
Cases of Note: 2005–2015
From January 2005 to June 2015 eleven cases were referred
to the Bacterial Reference Department, Public Health England
that were identified as positive for M. pneumoniae that were
of particular note. The majority of cases were patients with
lower respiratory tract infection. Stevens-Johnson syndrome is an
immune-mediated hypersensitivity complex typically involving
the skin and mucous membranes. Two cases of Stevens-Johnsons
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FIGURE 3 | Distribution of MLST sequence types for 57 M. pneumoniae clinical isolates in the 4-yearly epidemic cycles observed in the UK. Year
groups indicative of epidemic periods are listed on the x-axis. Sequence types (ST) 1–12 are listed in the key and indicated with differing colors. Allelic profiles are
available on http://pubmlst.org/mpneumoniae.
FIGURE 4 | Distribution of MLVA types in positive M. pneumoniae clinical specimens/isolates collated into the 4-yearly epidemic cycles observed in
the UK. Year groups indicative of epidemic periods are listed on the x-axis. MLVA profiles are listed in the key and indicated with differing colors.
syndrome were noted in 2009 and 2010 in male children aged
8 and 6 respectively. Two cases were noted in respiratory
specimens in immunocompromised patients following extra-
pulmonary organ transplantation (2013 and 2015). Infection
in donor transplant patient respiratory secretions was also
noted in 2015. M. pneumoniae was detected by qPCR in the
nasopharyngeal aspirate but not the cerebral spinal fluid (CSF)
of a patient with pneumonia and reactive transverse myelitis in a
child in 2005, and in the bronchoalveolar lavage of a child with
encephalitis and seizures in 2011. In 2011 a young adult patient
presented post respiratory tract infection with encephalitis and
transverse myelitis that progressed to tetraplegia with ventilator
dependency. M. pneumoniae was confirmed by qPCR on throat
swab specimens taken 19 and 21 days post onset but was not
detected in concurrent CSF specimens (Chalker et al., 2012b).
Detection ofM. pneumoniae in CSF is unusual and it is postulated
that neurological manifestation of M. pneumoniae infection is
antibody mediated rather than by direct presence of the bacteria
itself (Waites and Talkington, 2004). Of 68 CSF specimens
referred only 1 positive case was detected in 2010, in a child with
a ventriculoperitoneal shunt, in which contamination of the CSF
during sampling could not be excluded. In 2012 M. pneumoniae
was detected by qPCR in the lung tissue of two co-habiting adults
that both suffered sudden fatal collapse. This was presumed a
secondary infection as one of the two patients also had confirmed
Staphylococcus aureus infection.
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FIGURE 5 | Distribution of P1 type in 4-yearly epidemic cycles observed in the UK for positive M. pneumoniae clinical specimens/isolates. Year groups
indicative of epidemic periods are listed on the x-axis. P1 types are listed in the key and indicated with differing colors.
TABLE 1 | Incidence of M. pneumoniae positive laboratory reports per million persons.
Year Incidence (per million persons in overall population)
0–4 years 5–9 years 10–14 years 15–24 years 25–44 years 45–64 years 65+ years Unknown Total
Serology + PCR 2010 1.17 1.35 0.99 1.40 2.09 1.44 0.61 0.00 9.05
2011 1.14 1.83 1.16 1.51 2.40 1.28 0.87 0.02 10.21
2012 1.45 1.47 1.15 1.45 2.84 2.05 1.22 0.00 11.63
2013 0.61 0.95 0.74 0.93 1.77 1.82 1.42 0.00 8.25
2014 0.82 0.78 0.47 0.89 2.09 1.10 1.31 0.02 7.47
2015* 1.78 1.22 0.70 1.15 3.07 1.88 1.32 0.00 11.11
Average 1.16 1.27 0.87 1.22 2.38 1.60 1.13 0.01 9.62
*Data for 2015 from January to June and rates adjusted for half-year data were collected.
DISCUSSION
Laboratory reports show that cyclic epidemics ofM. pneumoniae
infections in EW recur every 4 years on average, concurrent
with annual seasonal fluctuations with incidence peaking and
dipping in the winter and summer respectively. The reduction
in clarity and magnitude of epidemic periods in recent years
could be indicative of a genuine reduction in cases, increasing
population pulmonary health, or reflect the changing nature
of testing strategies moving away from techniques such as
complement fixation. Overall incidence, although declining over
the period 1989–2015, has remained static since 2010 and age-
specific differences in epidemic period incidence were noted for
the limited periods studied. Annual notification rate in 2010–
2015 was highest in 15–44 year olds perhaps reflecting reliance
on serological confirmation or infection. Globally, epidemics of
M. pneumoniae are considered to occur every 3–7 years, however
recent epidemiological studies have documented varying trends
in epidemic patterns. Serological studies performed in Denmark
showed a pattern of M. pneumoniae infections over a 50
year period from 1946 through 1995 with endemic disease
transmission punctuated with cyclic epidemics every 3–5 years
(Lind et al., 1997). In Jerusalem, historically, epidemics were
observed every 3–5 years with seasonal peaks in October and
early spring; however, since autumn 2014 a constant rate of
infection has been observed, diverging from the historical pattern
(Nir-Paz et al., 2012). Indeed, similar to the data for EW; 3-
yearly cyclic epidemic periods with declining magnitude have
been documented in Japan from 1979 to 1999 (Ito et al.,
2001).
Speculations regarding the mechanisms driving fluctuations
in population incidence of M. pneumoniae infections have
included decline in immunity or increase of the immunologically
naive population level (Chalker et al., 2011a) or shifts in
the proportion of individual strains with specific P1 type or
concurrent increased incidence of several strains. Additionally, it
is believed that the genotype ofM. pneumoniaemay be changing,
generating diverse genetic material in each epidemic with a
study reporting the detection of polyclonal strains in a single
epidemic (Pereyre et al., 2012). Recent modeling of epidemic
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peaks has suggested that fluctuations may be attributable to
minor variations in the duration of immunity at the population
level (Omori et al., 2015). Speculation that a shift in P1 adhesin
type may be the cause of epidemics has been disputed with
evidence indicating the presence of multiple P1 adhesin types
in observed increases of infection (Sasaki et al., 1996; Dégrange
et al., 2009; Pereyre et al., 2012). It was hypothesized that a
decline in immunity or an increase of the immunologically
naïve population may result in the 4-year cycle of epidemic
periods (Chalker et al., 2011a). In other geographical locations,
it has also been observed that multiple P1 types can be detected
during outbreaks, and it has been suggested that although
immunological pressure may favor shifts of P1 type, a co-
circulation of P1 types appears to be common (Nilsson et al.,
2010; Dumke et al., 2015). This is further supported by the
presence of multiple MLST types within specimens in EW,
reflecting the concurrent presence of strains of varied genetic
lineage. As expected an increase in molecular detection of
infection is noted, with declining use of culture. Macrolide
resistance has recently been documented at 9.3% found in adult
patients only (Brown et al., 2015a) and is also of concern
in children in other countries (Meyer Sauteur et al., 2014a).
However, this was derived from results of specimens submitted
to the reference laboratory which may be biased toward those
developing resistance during treatment and one patient was
documented to have received macrolides prior to sampling
therefore this level may be an over-representation to the actual
level in the community.
Extrapulmonary complications of M. pneumoniae
infection can arise involving the skin and the nervous,
cardiovascular, renal, gastrointestinal, musculoskeletal, and
hematologic systems. The presence of M. pneumoniae in these
extrapulmonary sites has been confirmed by PCR as well as
culture (Koletsky and Weinstein, 1980; Kasahara et al., 1985;
Narita et al., 1996; Saïd et al., 1999; Bar Meir et al., 2000).
Complications that occur within the central nervous system
(CNS) are recognized as the most common extrapulmonary
manifestations of M. pneumoniae infections. A recent study
of 1988 children with encephalitis showed M. pneumoniae as
the most common causative agent (Bebear and Robertson,
1996). It is thought that the host immune response that
develops after M. pneumoniae infection contributes to these
complications as well as contributing to autoimmunity (Waites
and Talkington, 2004). The mechanisms that result in these
neurological manifestations of M. pneumoniae infection are not
completely understood however, immune-mediated mechanism
are suspected due to the development of cross-reactive antibodies
to the brain and other neurological structures (Waites et al.,
2008). PCR testing of 68 CSF specimens in EW resulted in
detection of M. pneumoniae DNA in a single specimen in
which contamination during sampling could not be excluded.
Consideration to testing of CSF specimens in tandem with paired
respiratory specimens should be given as in practice detection
of M. pneumoniae in CSF is extremely rare and positive patients
may be detected using pulmonary specimens.
In summary, epidemics of M pneumoniae infections
recur every 4 years on average in EW affecting all age
groups, predominantly children and adults <44 years of
age. Macrolide resistance has recently been documented at 9.3%
and extrapulmonary complications can be severe.
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